ResMed (RMD) Tops Q2 EPS by 22c, Beats on Revenues

ResMed (NYSE: RMD) reported Q2 EPS of $1.00, $0.22 better than the analyst estimate of $0.78. Revenue for the quarter came in at $601 million versus the consensus estimate of $580.32 million.

For earnings history and earnings-related data on ResMed (RMD) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance